Acadia Pharmaceuticals Inc (NASDAQ: ACAD) started the day on Thursday, with a price decrease of -3.24% at $17.02, before settling in for the price of $17.59 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $14.15-$32.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 27.73%. Meanwhile, its Annual Earning per share during the time was 28.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 294.44%. This publicly-traded company’s shares outstanding now amounts to $166.39 million, simultaneously with a float of $165.12 million. The organization now has a market capitalization sitting at $2.83 billion. At the time of writing, stock’s 50-day Moving Average stood at $15.55, while the 200-day Moving Average is $17.52.
Acadia Pharmaceuticals Inc (ACAD) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Acadia Pharmaceuticals Inc’s current insider ownership accounts for 0.76%, in contrast to 96.20% institutional ownership. According to the most recent insider trade that took place on Aug 19 ’24, this organization’s EVP, CHIEF FINANCIAL OFFICER sold 9,733 shares at the rate of 15.28, making the entire transaction reach 148,720 in total value, affecting insider ownership by 43,735. Preceding that transaction, on Aug 19 ’24, Company’s EVP, COO, HEAD OF COMMERCIAL sold 9,534 for 15.28, making the whole transaction’s value amount to 145,680. This particular insider is now the holder of 52,177 in total.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
Acadia Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 294.44% and is forecasted to reach 0.77 in the upcoming year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Let’s observe the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). It’s Quick Ratio in the last reported quarter now stands at 2.11. The Stock has managed to achieve an average true range (ATR) of 0.62. Alongside those numbers, its PE Ratio stands at $22.03, and its Beta score is 0.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.05. Similarly, its price to free cash flow for trailing twelve months is now 13.97.
In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.77, a figure that is expected to reach 0.21 in the next quarter, and analysts are predicting that it will be 0.77 at the market close of one year from today.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
If we take a close look at the recent performances of Acadia Pharmaceuticals Inc (NASDAQ: ACAD), its last 5-days Average volume was 1.26 million that shows plunge from its year to date volume of 1.68 million. During the previous 9 days, stock’s Stochastic %D was recorded 72.17% While, its Average True Range was 0.68.
Raw Stochastic average of Acadia Pharmaceuticals Inc (ACAD) in the period of the previous 100 days is set at 54.25%, which indicates a major fall in contrast to 61.59% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 48.62% that was lower than 49.33% volatility it exhibited in the past 100-days period.
